LUMIVATAMIG
UNII NLU8FTP8AP
Substance Identification & Data
This profile provides standardized clinical and technical data for Lumivatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NLU8FTP8AP.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3035406-55-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
NLU8FTP8AP
3035406-55-1
N/A
Detailed Substance Profile
Preferred Name
LUMIVATAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13593
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Lumivatamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Lumivatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Lumivatamig
Common Names & Synonyms
H-gamma1 heavy chain anti-CLDN18 humanized (H) (1-450) hole [VH (Homo sapiens IGHV1-46*01 (86.7%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120)-Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1v14 CH2 A1.3, A1.2, 14-G1v75 CH3 C5, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83-1 CH3 R115 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238) (234-343), CH3 Y5>C (352), D12 (359), L14 (361), T22>S (369), L24>A (371), Y86>V (410), H115>R (438) (344-448), CHS (449-450)) (121-450)], (223-220')-disulfide with common L-kappa light chain chimeric (L') (1'-220') [V-KAPPA Musmus/Homsap (Mus musculus IGKV8-19*01 (87.1%) -IGKJ2*01 (100%)/Homo sapiens IGKV4-1*01 (85.1%) -IGKJ2*01 (91.7%), Q120>G (106'), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; H-gamma1-17mer-scFvlh heavy chain anti-CLDN18 and anti-CD3D/CD3E (H'') (1''-715'') knob [H-gamma1 heavy chain anti-CLDN18 humanized (H'') (1''-449'') knob [VH (Homo sapiens IGHV1-46*01 (86.7%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT [8.8.13](26''-33''.51''-58''.97''-109'')) (1''-120'')-Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1v14 CH2 A1.3, A1.2, 14-G1v74 CH3 C10, 14-G1v32 CH3 W22 (knob)(CH1 K120 (217'') (121''-218''), hinge 1-15 (219''-233''), CH2 L1.3>A (237''), L1.2>A (238'') (234''-343''), CH3 S10>C (357''), D12 (359''), L14 (361''), T22>W (369'') (344''-448''), CHS K2>del (449'')) (121''-449'')] -17-mer (alanyl-tris(tetraglycyl-seryl)-alanyl) linker (450''-466'') -scFvlh anti-CD3D/CD3E humanized and chimeric (467''-715'') [V-LAMBDA humanized (Homo sapiens IGLV7-46*01 (81.1%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (492''-500''.518''-520''.557''-565'')) (467''-575'') -15-mer tris(tetraglycyl-seryl) linker (576''-590'') -VH Musmus/Homsap (Mus musculus IGHV10-1*04 (91.0%) -(IGHD) -IGHJ3*01 (93.3%) A128>S (715'')/Homo sapiens IGHV3-73*01 (83.0%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (710''), CDR-IMGT [8.10.16] (616''-623''.641''-650''.689''-704'')) (591''-715'')]]; (223''-220''')-disulfide with common L-kappa light chain chimeric (L''') (1'''-220''') [V-KAPPA Musmus/Homsap (Mus musculus IGKV8-19*01 (87.1%) -IGKJ2*01 (100%)/Homo sapiens IGKV4-1*01 (85.1%) -IGKJ2*01 (91.7%), Q120>G (106'''), CDR-IMGT [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'''), V101 (197''')) (114'''-220''')]; dimer (229-229'': 232-232'':352-357'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from CHO-K1 cell line, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa
immunoglobulin (H-gamma1_L-kappa)_(H-gamma1-17mer-scFvlh_L-kappa), anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], anti-[Homo sapiens CD3D (CD3 delta) and CD3E (CD3 epsilon, Leu-4) dimer], humanized and chimeric monoclonal antibody, bispecific, trivalent (lumivatamig)
lumivatamig [INN]
